Demonstration of the Presence of a Carbonyl Stress in the Hair Follicles of Postpartum Women

May 14, 2020 updated by: Pierre Fabre Dermo Cosmetique
In this study, the investigator will try to highlight the presence of carbonyl compounds in the hair follicles of postpartum women by comparing these compounds before and after delivery.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

At the cutaneous level, oxidative stress induces the formation of carbonyl compounds which, by binding to proteins, produce non-functional adducts inducing cutaneous aging. This mechanism is called "carbonyl stress".

During pregnancy, estrogen increases massively, stimulates the whole body and prolongs the life of the hair (slower passage in telogen phase).

After delivery, estrogen levels drop, resulting in a massive and simultaneous hair loss that should have "naturally" fallen earlier. In addition, birth is a stressful stage for most moms. This stress and excessive fatigue and possibly a return to work may also be responsible for hair loss.

Is the carbonyl stress also present in the scalp and can it be one of the mechanisms involved in the occurrence of postpartum hair loss? To demonstrate this, samples of hair follicles are taken. The proteins are extracted from the samples and then assayed. The oxidized (carbonyl) proteins are labeled with specific fluorescent probes

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Toulouse, France, 31059
        • Hopital Purpan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

Criteria related to the Population:

  • Pregnant woman (≥ 33 weeks of amenorrhea)
  • Woman aged between 18 and 40 years (included)
  • Phototype I to IV included according to Fitzpatrick's classification
  • Affiliation to a French social security scheme or benefiting from such a scheme
  • Signed informed consent form

Exclusion Criteria:

Criteria related to the Population:

  • High risk or pathological pregnancy, according to the opinion of the investigator
  • Deprivation of liberty by administrative or judicial decision or subject under guardianship
  • Impossibility, according to the investigator, to comply with the requirements of the protocol
  • Linguistic or psychic incapacity to sign informed consent
  • Concomitant participation in a clinical study that may interfere with the results of the study, according to the opinion of the investigator (excluding observational studies)

Criteria related to Pathology :

  • Alopecia causing hair loss on the upper part of the scalp
  • Dermatological pathology or evolving cutaneous lesion in the scalp
  • Known history of hepatitis B and C, HIV
  • Past or present neoplastic condition
  • Acute evolving pathology
  • Gestational diabetes treated with insulin

Criteria related to Treatments:

  • Treatment of general thyroid disorders initiated or modified for less than 3 months prior to inclusion (or change of specialty for less than 3 months)
  • Systemic treatment affecting hair growth taken for at least 4 weeks during the 3 months prior to inclusion
  • Systemic treatment: nonsteroidal anti-inflammatory drug, corticosteroid, antibiotic, antihistamine taken for 5 consecutive days within 2 weeks prior to inclusion or that may interfere with the results of the study according to the investigator,
  • Dermal use, for at least 4 weeks, of Minoxidil, Aminexil within 3 months prior to inclusion
  • Dermal use in the 4 weeks prior to inclusion, of any product that may be active on the hair follicle and scalp or may affect the dosage of carbonyl compounds (including hair dyes)
  • Last shampoo less than 2 days before the inclusion and application of styling / care products (gel, lacquer, wax, conditioner ...) or water between the last shampoo and the inclusion

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Intra individual
Before and after pregnancy, hair follicles will be analysed
The hair follicles will be collected by strand of 5 to 6 hairs approximately in the scalp (centro-parietal part), in order to obtain 20 follicles with epithelial sheath.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of biological evaluation
Time Frame: 1st sample: inclusion visit (up to 8 weeks before delivery)- 2nd sample: end of study visit (10 to 16 weeks after delivery)
Evaluation of the quantity of carbonyl compounds measured in the hair follicles taken before and after delivery.
1st sample: inclusion visit (up to 8 weeks before delivery)- 2nd sample: end of study visit (10 to 16 weeks after delivery)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety evaluation
Time Frame: From inclusion to end of study
Adverse events evaluation for all subjects, all along the study
From inclusion to end of study

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Christophe VAYSSIERE, MD

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 15, 2018

Primary Completion (Actual)

September 6, 2019

Study Completion (Actual)

December 16, 2019

Study Registration Dates

First Submitted

October 1, 2019

First Submitted That Met QC Criteria

January 17, 2020

First Posted (Actual)

January 23, 2020

Study Record Updates

Last Update Posted (Actual)

May 18, 2020

Last Update Submitted That Met QC Criteria

May 14, 2020

Last Verified

May 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • STRESSCARBONYL2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Proof of concept study, with confidential data

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Telogen Effluvium

Clinical Trials on Hair follicles sampling

Subscribe